Capmatinib inMETExon 14–Mutated orMET-Amplified Non–Small-Cell Lung Cancer | Zendy

Jürgen Wolf | Zendy; Takashi Seto | Zendy; JiYoun Han | Zendy; Noemı́ Reguart | Zendy; Edward B. Garon | Zendy; Harry J.M. Groen | Zendy; Daniel S.W. Tan | Zendy; Toyoaki Hida | Zendy; Maja J.A. de Jonge | Zendy; Sergey Orlov | Zendy; Egbert F. Smit | Zendy; Pierre-Jean Souquet | Zendy; Johan Vansteenkiste | Zendy; Maximilian J. Hochmair | Zendy; Enriqueta Felip | Zendy; Makoto Nishio | Zendy; Michael Thomas | Zendy; Kadoaki Ohashi | Zendy; Ryo Toyozawa | Zendy; Tobias R. Overbeck | Zendy; Filippo de Marinis | Zendy; Tae Min Kim | Zendy; Eckart Laack | Zendy; Anna Robeva | Zendy; Sylvie Le Mouhaër | Zendy; Maeve Waldron-Lynch | Zendy; B. Sankaran | Zendy; O. Alejandro Balbin | Zendy; Xiaoming Cui | Zendy; Monica Giovannini | Zendy; Mikhail Akimov | Zendy; Rebecca S. Heist | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Capmatinib inMETExon 14–Mutated orMET-Amplified Non–Small-Cell Lung Cancer

Author(s) -

Jürgen Wolf,

Takashi Seto,

JiYoun Han,

Noemı́ Reguart,

Edward B. Garon,

Harry J.M. Groen,

Daniel S.W. Tan,

Toyoaki Hida,

Maja J.A. de Jonge,

Sergey Orlov,

Egbert F. Smit,

Pierre-Jean Souquet,

Johan Vansteenkiste,

Maximilian J. Hochmair,

Enriqueta Felip,

Makoto Nishio,

Michael Thomas,

Kadoaki Ohashi,

Ryo Toyozawa,

Tobias R. Overbeck,

Filippo de Marinis,

Tae Min Kim,

Eckart Laack,

Anna Robeva,

Sylvie Le Mouhaër,

Maeve Waldron-Lynch,

B. Sankaran,

O. Alejandro Balbin,

Xiaoming Cui,

Monica Giovannini,

Mikhail Akimov,

Rebecca S. Heist

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2002787

Subject(s) - exon , lung cancer , cancer research , mutation , cancer , biology , medicine , oncology , genetics , microbiology and biotechnology , gene

Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research